These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
136 related articles for article (PubMed ID: 9475770)
21. Benign prostatic hyperplasia: from A - Z. Elhilali MM; Nickel JC Can J Urol; 2003 Apr; 10(2):1799-802. PubMed ID: 12773230 [TBL] [Abstract][Full Text] [Related]
22. Finasteride in the treatment of patients with moderate symptoms of benign prostatic hyperplasia. Magoha GA East Afr Med J; 1998 May; 75(5):260-3. PubMed ID: 9746993 [TBL] [Abstract][Full Text] [Related]
23. Benign prostatic hyperplasia--review of treatment options. Oehlke KJ; Branaugh ML S D Med; 2009 May; 62(5):202-3. PubMed ID: 19489345 [No Abstract] [Full Text] [Related]
28. Waxing and waning gynecomastia: an indication of noncompliant use of prescribed medication. Miller JA; Pramanik B; Gilhooly P South Med J; 1999 Jun; 92(6):615-7. PubMed ID: 10372857 [TBL] [Abstract][Full Text] [Related]
29. Selecting therapy for maintaining sexual function in patients with benign prostatic hyperplasia. Nehra A BJU Int; 2005 Aug; 96(3):237-43. PubMed ID: 16042709 [TBL] [Abstract][Full Text] [Related]
31. 5alpha-Reductase inhibitor treatment of prostatic diseases: background and practical implications. Dörsam J; Altwein J Prostate Cancer Prostatic Dis; 2009; 12(2):130-6. PubMed ID: 19030020 [TBL] [Abstract][Full Text] [Related]
32. Finasteride for benign prostatic hyperplasia. Hasinski S; Miller JL; Rose LI Am Fam Physician; 1992 Nov; 46(5):1511-4. PubMed ID: 1279965 [TBL] [Abstract][Full Text] [Related]
34. Effect of long-term administration of finasteride (MK-906), an inhibitor of 5 alpha-reductase, in patients with benign prostatic hyperplasia. Yoshida O; Oishi K; Okada Y; Mizutani Y; Itokawa Y; Tomoyoshi T; Okada K; Komatz Y; Matsuda T; Takeuchi H Hinyokika Kiyo; 1996 Apr; 42(4):323-31. PubMed ID: 8693970 [TBL] [Abstract][Full Text] [Related]
35. [Using doxasosine and finasteride combination in the treatment of prostate adenoma]. Bogdanov AB; Luk'ianov IV; Veliev EI Urologiia; 2006; (5):59-63. PubMed ID: 17444154 [TBL] [Abstract][Full Text] [Related]
36. [Therapy of benign prostatic hyperplasia with finasteride and doxazosin -- long-term studies support the combination]. Hausmann R; Thalmann G; Reich O; Steif CG Aktuelle Urol; 2004 Sep; 35(5):339-42. PubMed ID: 15383991 [No Abstract] [Full Text] [Related]
37. The impact of 5-alpha-reductase inhibitors on the number of prostatectomies for benign prostatic hyperplasia. Agha AH; Roy JB; Culkin DJ; Lyon K Adv Ther; 1995; 12(6):361-6. PubMed ID: 10163332 [TBL] [Abstract][Full Text] [Related]
38. [Medical treatment of benign prostatic hyperplasia. The efficacy of finasteride depends on prostatic volume]. Granados Loarca EA Arch Esp Urol; 1999 Apr; 52(3):201-8. PubMed ID: 10371735 [TBL] [Abstract][Full Text] [Related]
39. [Comparative evaluation of the effectiveness and safety of combined drug therapy of patients with benign prostatic hyperplasia with finasteride and alfuzozine]. Loran OB; Pushkar' DIu; Rasner PI Urologiia; 2002; (1):19-22. PubMed ID: 11877966 [TBL] [Abstract][Full Text] [Related]
40. Finasteride in the treatment of benign prostatic hyperplasia. Ekman P; Andersen JT; Wolf H Acta Urol Belg; 1996 Mar; 64(1):IX-XII. PubMed ID: 8659328 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]